Significant Accounting Policies and Recent Accounting Pronouncements (Details Narrative) - USD ($)
|
|
3 Months Ended |
6 Months Ended |
|
|
|
|
|
|
Jul. 02, 2019 |
Dec. 31, 2019 |
Dec. 31, 2019 |
Dec. 31, 2018 |
Jul. 18, 2019 |
Jul. 01, 2019 |
Jun. 30, 2019 |
May 09, 2019 |
Sep. 30, 2018 |
Jun. 30, 2018 |
| Treasury Stock Shares |
|
659,448
|
659,448
|
|
|
|
228,218
|
|
228,218
|
0
|
| Treasury Stock, at cost (659,448 shares and 228,218 shares as of December 31, 2019 and June 30, 2019, respectively |
|
$ (146,000)
|
$ (146,000)
|
|
|
|
$ (91,000)
|
|
|
|
| Computation of diluted shares |
|
|
72,400,000
|
70,100,000
|
|
|
|
|
|
|
| Operating lease right-of-use assets |
|
|
|
|
|
$ 670,000
|
|
|
|
|
| Operating lease liabilities |
|
615,000
|
$ 615,000
|
|
|
$ 670,000
|
|
|
|
|
| Term of lease |
12 months
|
|
|
|
|
|
|
|
|
|
| Impairment expense of operating lease |
|
|
(643,000)
|
|
|
|
|
|
|
|
| Amortization of the right-of-use asset |
|
27,000
|
27,000
|
|
|
|
|
|
|
|
| Operating lease carrying value |
|
0
|
0
|
|
|
|
|
|
|
|
| License Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
| Additional payments payable upon achievement of certain milestones under agreement by related party |
|
24,000,000
|
24,000,000
|
|
|
|
|
|
|
|
| Payment due following commencement of first phase III clinical trial of Brilacidin |
|
1,000,000
|
1,000,000
|
|
|
|
|
|
|
|
| Non-refundable payment |
|
400,000
|
400,000
|
|
|
|
|
|
|
|
| Payment due upon filing of a marketing approval application |
|
$ 1,000,000
|
$ 1,000,000
|
|
$ 1,000,000
|
|
|
|
|
|
| Series B Preferred Stock [Member] |
|
|
|
|
|
|
|
|
|
|
| Conversion Price |
|
$ 0.04
|
$ 0.04
|
$ 0.09
|
|
|
|
|
|
|